EVALUATING CLINICAL EFFICACY OF MANASHILADI GHRITA AND ALSTONIASCHOLARIS IN THE MANAGEMENT OF ASTHMA COPD OVERLAPPING SYNDROME(ACOS) WITH SPECIAL REFERENCE TO TAMAKASHWASA A COMPARATIVERANDOMISED DOUBLE ARM CLINICAL TRIA

All India Institute Of Ayurveda0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•3. Having sign and symptoms of Tamak Shwas/ ACOâ?? swasakruchhrata (dyspnoea), kanthodhwansa (speak with difficulty), kasa (cough), ghurghurka sabda ( wheezing /rhonchi)
•4. Pulmonologist diagnosed patient of ACO • Post bronchodilator increase of forced expiratory volume in 1 second (FEV1) >= 12% and >= 400 mL, and eosinophilia in sputum in addition to a personal history of asthma. • High total immune globulin E (IgE), personal history of atopy, and a post bronchodilator increase of FEV1 >= 12% and >= 200 mL on >= 2 occasions. • History of evidence of atopy, elevated total IgE, aged >= 40 years, smoking > 10 pack-years, post-bronchodilator FEV1 < 80% predicted and FEV1/forced vital capacity (FVC) < 70%.
•5. Not undergoing exercise training program or any other lung rehabilitation therapy.
•6. BMI < 25
•7. Smokers and ex-smoker with smoking history>=10 pack-years.
•8. Patient having allergic diseases or any family history of allergic diseases.
•9. Ability to demonstrate compliance with handy-inhaler, a salbutamol Meter Dose Inhaler, and the activity monitor; perform acceptable Pulmonary Function Tests; an exercise stress test and can follow study procedures. (Note: GOLD-Global Initiative for Chronic Obstructive Lung Diseases, MRC- Medical Research Council).
•10. Vitamin D3 deficient : Serum 25(OH)D <30ng/ml

•a. ACOS with life threatening complications like cor-pulmonale, respiratory failure, pneumothorax and polycythemia.
•b. Any history of previous chronic infectious respiratory disease like tuberculosis, URTI, acute bronchitis, pneumonia.
•c. Patient taking steroid therapy from long duration (systemic or inhaled corticosteroid)
•d. Diagnosis of renal or cardiac asthma.
•e. History of cystic fibrosis.
•f. Past or current malignancy within 5years.
•g. Pregnant ladies and lactating mothers.
•h. History of any adverse drug reactions.
•i. Patients having positive HIV1 and 2 or positive Hepatitis B.
•j. Patients having end stage hepatic dysfunction (defined aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 4 times of the upper normal limit) or severe renal dysfunction (defined as S. creatinine > 1.2 mg/dl),severely compromised cardiac function (EF < 30% ).
•k. Patient with poorly controlled Hypertension ( > 180 / 100 mm Hg). l. BMI >25 kg/m2

发起方